Point72 Hong Kong’s Marker Therapeutics MRKR Stock Holding History

Point72 Hong Kong’s Portfolio MRKR Stock Details MRKR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-54	Closed	-$1K	–	2205
2021 Q1	$1K	Buy	+54	New	+$1.24K	﹤0.01%	1727

Other funds holding MRKR

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Point72 Hong Kong's MRKR Position: Q2 2021 in Review

Point72 Hong Kong sold out of Marker Therapeutics (MRKR) in Q2 2021, closing a stake of 54 shares — an estimated $1K sold.

Point72 Hong Kong first reported a position in MRKR in Q1 2021 and held it in 1 quarter. The position peaked at $1K in Q1 2021. 74 funds tracked by Wall St. Rank hold MRKR as of Q2 2021.

Point72 Hong Kong reported no remaining Marker Therapeutics position as of Q2 2021 after selling out during the quarter.
Point72 Hong Kong sold 54 Marker Therapeutics shares in Q2 2021, an estimated $1K.
Point72 Hong Kong first reported a position in Marker Therapeutics in Q1 2021 and held it in 1 quarter.
Point72 Hong Kong's Marker Therapeutics position peaked at $1K in Q1 2021.
74 funds tracked by Wall St. Rank held Marker Therapeutics as of Q2 2021.

Based on Point72 Hong Kong's 13F filing for Q2 2021, filed 16 Aug 2021.